Vitamin K Bone Health Meta-analysis: What the Evidence Says

Quick Answer

Vitamin K Bone Health Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Medication-related osteonecrosis of the jaw (MRONJ) is a rare but potentially debilitating adverse effect associated primarily with antiresorptive therapies (e.g., bisphosphonates and denosumab) and, less commonly, certain antiangiogenic/targeted agents. [Daneshvar Alireza (2026); evidence level 1]
• Vitamin D, a secosteroid hormone, is crucial for calcium absorption and bone mineralization and is positively associated with bone mineral density. [Daneshvar Alireza (2026); evidence level 1]
• Fracture is a common complication of DM, especially those with longer diabetes duration, vascular complications, and due to the use of specific medications. BMD is a usual significant indicator of bone health and a primary predictor of fracture risk. [Kashmoola Israa O. (2026); evidence level 4]
• A low BMD means weaker bones and is often indicative of osteoporosis. Evidence stares that T2DM patients routinely reveal average or augmented BMD levels compared to those with type 1 DM (T1DM) or those without T2DM; nevertheless, they experience inappropriate risk of fractures. [Kashmoola Israa O. (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For vitamin k bone health meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Daneshvar Alireza (2026). Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. DOI: 10.1186/s12903-026-08303-9. PMCID: PMC13270808. PMID: 41975407. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13270808/
• Kashmoola Israa O. (2026). Polypharmacy and Bone Health in Patients with Type 2 Diabetes Mellitus: A Narrative Review. DOI: 10.11005/jbm.25.975. PMCID: PMC13284594. PMID: 42316445. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Acces.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13284594/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.